FindTrial
Sign In

Lecanemab 10 mg/kg

DRUG6 trials

Sponsors

Eisai Inc., Second Affiliated Hospital, School of Medicine, Zhejiang University, Neurology Office of South Florida, First Affiliated Hospital of Wenzhou Medical University

Conditions

Alzheimer DementiaAlzheimer Dementia (AD)Alzheimer DiseaseAlzheimer Disease (AD)Alzheimer s DiseaseAlzheimer's DiseaseAlzheimers DiseaseMCI-AD, Early Stage Alzheimer's Disease

Phase 2

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
CompletedNCT01767311
Eisai Inc.Alzheimer's Disease
Start: 2012-12-20End: 2024-12-10Updated: 2026-03-04
The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.
Not yet recruitingNCT07212062
Neurology Office of South FloridaAlzheimers Disease
Start: 2025-12-01End: 2028-12-30Target: 60Updated: 2025-10-08

Phase 4

Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs
RecruitingNCT07604896
First Affiliated Hospital of Wenzhou Medical UniversityAlzheimer Dementia (AD), Alzheimer s Disease, MCI-AD, Early Stage Alzheimer's Disease
Start: 2026-01-01End: 2028-12-31Target: 200Updated: 2026-05-22

Unknown Phase

Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab
RecruitingNCT06741553
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAlzheimer Disease, Mild Cognitive Impairment (MCI)
Start: 2024-06-28End: 2027-06-30Target: 120Updated: 2025-09-03
Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research
Not yet recruitingNCT07152418
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAlzheimer Dementia, Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Start: 2025-09-01End: 2028-09-01Target: 120Updated: 2025-09-03
Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice
Not yet recruitingNCT07505095
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAlzheimer Dementia, Alzheimer Disease (AD), MCI-AD, Early Stage Alzheimer's Disease
Start: 2026-04-30End: 2028-01-31Target: 140Updated: 2026-04-01

Related Papers

Predicted natural progression as an Alzheimer's prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency
Alzheimer s & Dementia2025-03-012 citations
Model‐Based Assessment of Lecanemab Maintenance Dosing Regimen Shows Continued Suppression of Amyloid Plaque, Disease Progression
Alzheimer s & Dementia2024-12-012 citations
"Paradoxical” Cerebral Volume Changes in Anti‐Amyloid Immunotherapy Trials
Alzheimer s & Dementia2024-12-011 citations
Exposure‐response modeling to describe the change in brain amyloid following lecanemab administration in patients with early Alzheimer’s disease
Alzheimer s & Dementia2023-12-011 citations
Observations on biomarkers in Roche Abeta‐targeting monoclonal antibody trials
Alzheimer s & Dementia2023-12-011 citations
PK/PD analyses of ARIA‐E and isolated ARIA‐H in Lecanemab Clarity AD study
Alzheimer s & Dementia2023-12-01
Lecanemab
Amrita Journal of Medicine2023-07-01
Lecanemab for Patients With Early Alzheimer Disease
JAMA Network Open2023-04-1119 citations
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
Alzheimer s Research & Therapy2022-12-21255 citations
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease
Alzheimer s Research & Therapy2022-12-0934 citations
Neuropathological autopsy findings in an individual with Alzheimer’s disease who received long‐term treatment with lecanemab (BAN2401)
Alzheimer s & Dementia2022-12-016 citations
Diversity in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Lecanemab and Elenbecestat Early Alzheimer’s Disease Studies
Alzheimer s & Dementia2022-12-012 citations
Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.
2022-04-2539 citations
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
2021-04-17607 citations
DT‐01‐01: BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY
Alzheimer s & Dementia2019-07-013 citations